RTP Mobile Logo

Thursday, May 17, 2018, Washington, DC, 12:15 PM – 1:45 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 3 — PARP Inhibitors in Ovarian Cancer

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
11:45 AM – 12:15 PM
Registration and Lunch Buffet

12:15 PM – 1:45 PM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Paula J Anastasia, RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
Cedars-Sinai Medical Center
Los Angeles, California

Deborah K Armstrong, MD
Director, Breast and Ovarian Surveillance Service
Professor of Oncology, Gynecology and Obstetrics
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Jennifer G Filipi, MSN, NP
Massachusetts General Hospital
Center for Gynecologic Oncology
Boston, Massachusetts

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro Inc during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Module 1: Natural History of Ovarian Cancer (OC)


  • Biology of OC and specific histologic and clinical subtypes
  • Clinical presentation and staging
  • Role of tumor markers (CA-125) in disease monitoring

Module 2: Contemporary Clinical Algorithms in OC


  • Local and systemic treatment approaches for patients presenting with newly diagnosed OC
  • Biologic rationale for the use of “maintenance therapy” after chemotherapy
  • Mechanisms and determinants of platinum resistance
  • Defining and prioritizing treatment options for platinum-sensitive versus platinum-resistant recurrent disease
  • Deciding between bevacizumab, a PARP inhibitor and no further maintenance therapy for patients with platinum-sensitive disease; role of BRCA1/2 mutation status in this decision
  • Long-term outcomes among women with and without BRCA mutations

Module 3: Genetic Testing in OC


  • Frequency and clinical significance of BRCA germline and somatic mutations
  • Similarities and differences among available genetic testing platforms; role of extended panel testing/next-generation sequencing
  • Genetic counseling for patients with OC and their family members
  • Identification of “BRCA-like” and other genomic signatures (eg, HRD) that may predict benefit from PARP inhibition
  • Incidence and potential clinical relevance of other inherited mutations (eg, RAD51C, RAD51D, BRIP1)

Module 4: Available and Emerging Clinical Trial Data with PARP Inhibitors for the Treatment of OC


  • FDA indications for and optimal integration of niraparib, olaparib and rucaparib into contemporary OC treatment algorithms
  • Design, eligibility requirements and results from the Phase III NOVA (niraparib), SOLO-2 (olaparib) and ARIEL-3 (rucaparib) trials evaluating PARP inhibition as maintenance therapy in patients with platinum-sensitive OC
  • Stratification and related outcomes for various patient subsets (eg, BRCA mutation-positive, HRD-positive, wild-type) enrolled on Phase III PARP inhibitor maintenance trials
  • Biologic rationale for and ongoing trials evaluating PARP inhibitors in earlier lines of therapy or combined with other agents (eg, anti-angiogenics)

Module 5: Practical Integration of PARP Inhibitors into the Care of Patients with Recurrent OC


  • Toxicities associated with the use of available PARP inhibitors and strategies to prevent and/or ameliorate them; indications for the use of supportive care measures and/or treatment modifications/delays
  • Timing of and recommended monitoring protocols for toxicities observed in patients receiving PARP inhibitors
  • Differentiating between disease-related symptoms and treatment-associated adverse events in patients with advanced OC
  • Practical strategies to address common quality-of-life concerns in patients receiving treatment for advanced OC, including:
    • Insomnia
    • Anxiety
    • Peripheral neuropathy
    • Ascites
    • Anemia
    • Thrombocytopenia
    • Fatigue
    • Nausea and other gastrointestinal issues
    • Increases in creatinine
    • Issues with treatment adherence

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer (OC).

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Demonstrate knowledge of existing guidelines and consensus statements regarding the rationale for genetic testing and counseling for all patients with newly diagnosed OC regardless of family history.
  • Appreciate available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors to appropriately integrate these agents into the routine care of patients with OC.
  • Understand the dosing requirements and other practical considerations for the use of PARP inhibitors for women with OC to ensure appropriate administration and patient compliance.
  • Describe the potential toxicities of FDA-approved PARP inhibitors, and use this information to design effective monitoring strategies for patients receiving these agents.
  • Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with the use of PARP inhibitors for the treatment of platinum-sensitive and platinum-recurrent advanced OC.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with OC to optimize clinical and quality-of-life outcomes.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro Inc.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.



Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 3 — Ovarian Cancer. Onsite registration will be open starting at 11:45 AM (ET) on Thursday, May 17th.

If you are interested in standing by for seating (day of the program), please visit our registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.